Thyrocare Technologies: NCLT Approves Docon–API Holdings Merger, 51.02% Promoter Stake to Shift to API Holdings
Thyrocare Technologies Limited has informed the stock exchanges that the National Company Law Tribunal (NCLT), Mumbai Bench, has approved the proposed amalgamation of Docon Technologies Private Limited with API Holdings Limited, the parent company of the PharmEasy group.
The NCLT order was pronounced on August 31, 2026, marking an important step toward completion of the corporate restructuring involving the promoter group of Thyrocare Technologies.
NCLT Approves Scheme of Amalgamation
Docon Technologies and API Holdings had filed the Scheme of Amalgamation with the NCLT, Mumbai Bench, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.
The tribunal has now sanctioned the scheme.
However, the merger will become effective only after the prescribed conditions are completed or waived. One of the key remaining steps is filing the certified copy of the NCLT order with the Registrar of Companies (RoC) in Form INC-28.
Docon and API are expected to complete the required filings within the prescribed timelines.
Thyrocare’s 51.02% Promoter Holding Will Move to API Holdings
The most important point for Thyrocare shareholders is that Docon’s entire shareholding in Thyrocare will be transferred to API Holdings once the merger becomes effective.
Docon currently holds:
8.12 crore Thyrocare equity shares, representing 51.02% of the company’s paid-up share capital.
Following the implementation of the scheme, the same 8.12 crore shares will be held by API Holdings.
Therefore, the transaction represents a change in the entity holding the promoter-group stake rather than an increase or decrease in the aggregate promoter holding.
No Change in Overall Promoter Shareholding
The company has clarified that both Docon and API Holdings are currently members of Thyrocare’s Promoter Group.
After the merger:
- Docon’s holding will become Nil
- API Holdings will hold 8.12 crore shares
- API Holdings’ stake will be 51.02%
- Public shareholders will continue to hold 48.98%
- Total promoter and promoter-group ownership will remain 51.02%
In other words, the restructuring does not change the aggregate promoter/promoter-group shareholding in Thyrocare.
Shareholding Before and After the Merger
Before implementation, Docon Technologies holds 51.02% of Thyrocare, while public shareholders own 48.98%.
After the scheme becomes effective, Docon’s 51.02% stake will be transferred to API Holdings, with the public shareholding remaining unchanged at 48.98%.
The total number of outstanding shares also remains unchanged at approximately 15.92 crore shares.
Why the Restructuring Matters
The transaction is primarily a promoter-group restructuring.
Docon is a wholly owned subsidiary of API Holdings. Once Docon is amalgamated into API Holdings, its assets, liabilities, rights and obligations will transfer to API in accordance with the approved scheme.
For Thyrocare, the key consequence is the transmission of its promoter shareholding from Docon to API Holdings.
This means investors should not interpret the transaction as a fresh acquisition of Thyrocare shares by API Holdings from the public market. Instead, the existing promoter holding is being transferred as part of the approved amalgamation.
What Investors Should Watch
For Thyrocare shareholders, the immediate focus will be on the completion of the remaining procedural steps and the effective date of the merger.
Investors should particularly watch for:
- Filing of the certified NCLT order with the RoC
- Declaration of the Effective Date
- Formal transmission of Docon’s Thyrocare shares to API Holdings
- Subsequent shareholding disclosures
- Any future changes in promoter-group ownership
Importantly, based on the company’s disclosure, there is no change in the aggregate promoter and promoter-group holding, which remains at 51.02%.
Investor Takeaway
The NCLT’s approval removes a key regulatory hurdle for the proposed amalgamation of Docon Technologies with API Holdings.
For Thyrocare Technologies, the transaction will result in API Holdings replacing Docon Technologies as the entity directly holding the promoter group’s 51.02% stake.
The overall ownership structure, however, remains unchanged: promoters and the promoter group will continue to hold 51.02%, while public shareholders will retain 48.98%.
Therefore, the development is primarily a corporate restructuring within the promoter group, rather than a change in Thyrocare’s overall promoter ownership.
The next key milestone for investors is the completion of the RoC filing and the resulting Effective Date of the scheme.